SciELO - Scientific Electronic Library Online

 
vol.38 suppl.1Mercury contamination in breast milk of nursing mothers in gold mining municipalities of Antioquia, ColombiaVitamin D and risk of preeclampsia: A systematic review and meta-analysis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Biomédica

Print version ISSN 0120-4157

Abstract

MANTILLA, Carolina et al. Molecular and clinical characterization of Colombian patients suffering from type III glycogen storage disease. Biomédica [online]. 2018, vol.38, suppl.1, pp.30-42. ISSN 0120-4157.  https://doi.org/10.7705/biomedica.v38i0.3454.

Introduction:

Type III glycogen storage disease (GSD III) is an autosomal recessive disorder in which a mutation in the AGL gene causes deficiency of the glycogen debranching enzyme. The disease is characterized by fasting hypoglycemia, hepatomegaly and progressive myopathy. Molecular analyses of AGL have indicated heterogeneity depending on ethnic groups. The full spectrum of AGL mutations in Colombia remains unclear.

Objective:

To describe the clinical and molecular characteristics of ten Colombian patients diagnosed with GSD III.

Materials and methods:

We recruited ten Colombian children with a clinical and biochemical diagnosis of GSD III to undergo genetic testing. The full coding exons and the relevant exon-intron boundaries of the AGL underwent Sanger sequencing to identify mutation.

Results:

All patients had the classic phenotype of the GSD III. Genetic analysis revealed a mutation p.Arg910X in two patients. One patient had the mutation p.Glu1072AspfsX36, and one case showed a compound heterozygosity with p.Arg910X and p.Glu1072AspfsX36 mutations. We also detected the deletion of AGL gene 3, 4, 5, and 6 exons in three patients. The in silico studies predicted that these defects are pathogenic. No mutations were detected in the amplified regions in three patients.

Conclusion:

We found mutations and deletions that explain the clinical phenotype of GSDIII patients. This is the first report with a description of the clinical phenotype and the spectrum of AGLmutations in Colombian patients. This is importantto provide appropriate prognosis and genetic counseling to the patient and their relatives.

Keywords : Glycogen storage disease type III/diagnosis; glycogen; glycogen debranching enzyme system; glycogenolysis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )